Christian Bruns
Novartis
144 Papers
1.6K Citations
Christian Bruns is an academic researcher from Novartis. The author has contributed to research in topics: Somatostatin & Somatostatin receptor. The author has an hindex of 46, co-authored 109 publications. Previous affiliations of Christian Bruns include University of Göttingen.
Chat about Author
Papers
Partial Deficiency of Sphingosine-1-Phosphate Lyase Confers Protection in Experimental Autoimmune Encephalomyelitis
Andreas Billich,Thomas Baumruker,Christian Beerli,Marc Bigaud,Christian Bruns,Thomas Calzascia,Andrea Isken,Bernd Kinzel,Erika Loetscher,Barbara Metzler,Matthias Mueller,Barbara Nuesslein-Hildesheim,Bernadette Kleylein-Sohn +12 more
TL;DR: The data suggest Sgpl1 as a novel therapeutic target for the treatment of multiple sclerosis, demonstrated by the fact that the inducible KO mice are protected in experimental autoimmune encephalomyelitis (EAE), and T cell immigration into the CNS was found to be profoundly reduced.
Synthesis and Biological Evaluation of a Potent E-Selectin Antagonist
TL;DR: The efficient synthesis (10 linear steps) of the potent sLe(x) mimetic 2 is described, which shows a 30-fold improved affinity in a static, cell-free E-selectin-ligand binding assay and is predictive for the in vivo efficacy of test compounds.
42
Orally bioavailable competitive CCR5 antagonists.
Gebhard Thoma,Nuninger Francois,Marc Schaefer,Kayhan G. Akyel,Rainer Albert,Christian Beerli,Christian Bruns,Eric Francotte,Marcel Luyten,Duncan MacKenzie,Lukas Oberer,Markus Streiff,Trixie Wagner,Hansrudolf Walter,Gisbert Weckbecker,Hans-Guenter Zerwes +15 more
TL;DR: While all compounds tested were inactive on rodent CCR5, this series includes compounds that cross-react with the cynomolgus monkey (cyno) receptor, and one of these compounds, 26n, has good PK properties in cynos, and its overall favorable profile makes it a promising candidate for in vivo profiling in transplantation and other disease models.
37
Potent E-Selectin Antagonists
TL;DR: Modifications of the already known potent E-selectin antagonist 3 containing a cyclohexyllactic acid residue and a glucal-derived building block are reported on, which indicate topological-structure changes of 6 in the orientation of the neighboring fucose and galactose due to intramolecular steric interactions.
35
Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720
Gisbert Weckbecker,Charles Pally,Christian Beerli,Christoph Burkhart,Grazyna Wieczorek,Barbara Metzler,Randall E. Morris,Juergen Wagner,Christian Bruns +8 more
TL;DR: These studies are the first to demonstrate that AEB prolongs rat heart allograft survival safely as monotherapy and in combination with nonefficacious doses of cyclosporine, everolimus or FTY720, suggesting synergy.
31